Results 101 to 110 of about 5,838,181 (363)

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease

Nature Communications, 2019
Multiple myeloma is a cancer of the bone marrow that can induce bone disease. Here, the authors profile the transcriptome of bone-lining cells and find a targetable role of bone morphogenetic protein (BMP) signalling in myeloma-induced bone ...
Sarah Gooding, Sam W. Z. Olechnowicz, Emma V. Morris, Andrew E. Armitage, Joao Arezes, Joe Frost, Emmanouela Repapi, James R. Edwards, Neil Ashley, Craig Waugh, Nicola Gray, Erik Martinez-Hackert, Pei Jin Lim, Sant-Rayn Pasricha, Helen Knowles, Adam J. Mead, Karthik Ramasamy, Hal Drakesmith, Claire M. Edwards   +18 more
doaj   +1 more source

CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response

Advanced Science, EarlyView.
Tumor vascular remodeling is discussed from a chemokine‐centered perspective. This review summarizes the bidirectional, temporal, and tissue‐specific roles of CXC chemokines in regulating vascular function and immune accessibility. A functional vascular normalization score is introduced as a conceptual framework to integrate dynamic vascular and immune
Hongdan Chen, Yinde Huang, Juntong Wu, Ziying Yi, Yao Li, Zeyu Yang, Fan Zhang, Chong Li   +7 more
wiley   +1 more source

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6

Haematologica, 2015
The primary objective of this phase 1 study was to evaluate the safety and tolerability of the anti-glucose regulated protein 78 monoclonal immunoglobulin M antibody PAT-SM6 in subjects with relapsed or refractory multiple myeloma.
Leo Rasche, Johannes Duell, Inês C. Castro, Valentina Dubljevic, Manik Chatterjee, Stefan Knop, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Max S. Topp, Stephanie Brändlein   +10 more
doaj   +1 more source

Data from Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma

, 2023
Xufeng Chen, Patty Wong, Eric H. Radany, Jeremy M. Stark, Corentin Laulier, Jeffrey Y.C. Wong   +5 more
openalex   +1 more source

Artificial Intelligence for Bone: Theory, Methods, and Applications

Advanced Intelligent Discovery, EarlyView.
Advances in artificial intelligence (AI) offer the potential to improve bone research. The current review explores the contributions of AI to pathological study, biomarker discovery, drug design, and clinical diagnosis and prognosis of bone diseases. We envision that AI‐driven methodologies will enable identifying novel targets for drugs discovery. The
Dongfeng Yuan, Haicang Zhang, Liping Tong, Di Chen   +3 more
wiley   +1 more source

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1

Journal of Hematology & Oncology, 2010
Background Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies.
Li Zihai, Chiosis Gabriela, Bona Robert D, Usmani Saad Z   +3 more
doaj   +1 more source

myeloma protein

Citation: 'myeloma protein' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13487 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Accelerating Primary Screening of USP8 Inhibitors from Drug Repurposing Databases with Tree‐Based Machine Learning

Advanced Intelligent Discovery, EarlyView.
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng, Sharon Ai Er Lam, Wei Chun Lim, Hannah Hui Min Toh, Shi Jun Ang   +4 more
wiley   +1 more source

Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells

Haematologica, 2010
Background Multiple myeloma is an incurable malignancy of bone marrow plasma cells. Progression of multiple myeloma is accompanied by an increase in bone marrow angiogenesis.
Sally K. Martin, Peter Diamond, Sharon A. Williams, Luen Bik To, Daniel J. Peet, Nobutaka Fujii, Stan Gronthos, Adrian L. Harris, Andrew C.W. Zannettino   +8 more
doaj   +1 more source

Enhancement of immunogenicity of a BALB-c myeloma protein in BALB-c mice.

Journal of Immunology, 1974
Antiidiotypic antibodies to the BALB/c myeloma protein, LPC-1 (IgG2a(κ)) were induced in BALB/c mice by immunization with protein LPC-1 copolymerized with glutaraldehyde to either rabbit IgG or, preferably, C57BL IgG.
P. J. Peaker, L. Cicurei, A. Nisonoff
semanticscholar   +1 more source